Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

Another big pharma patent battle is underway. Amgen plans to take on Johnson & Johnson’s top-selling drug with a copycat version, seeking U.S. approval for its biosimilar of the psoriasis drug Stelara, which has been marketed in the U.S. since 2009.